Dericip 169.4mg/50.6mg Injection
Marketer
Cipla Ltd
Salt Composition
Etofylline (169.4mg) + Theophylline (50.6mg)
Overview Dericip 169.4mg/50.6mg Injection
AirDuo Respules (169.4mg/50.6mg) is a medication administered via injection to manage asthma and chronic obstructive pulmonary disease (COPD), a lung condition characterized by restricted airflow. Its mechanism of action involves bronchial muscle relaxation, facilitating easier breathing. Administration is solely by a physician or registered nurse, with dosage tailored to individual patient needs and response. Continuous use, as directed by your doctor, is crucial; premature discontinuation risks symptom recurrence and disease exacerbation. Complete disclosure of all other medications to your healthcare provider is essential due to potential interactions. Common, typically transient side effects include nausea, vomiting, dyspepsia, headache, and agitation. Report any concerning side effects immediately. Prior to treatment, inform your doctor of any existing heart, kidney, or liver conditions to ensure appropriate dosage. Similarly, disclose pregnancy, pregnancy plans, or breastfeeding.
Primary Ingredients of Dericip 169.4mg/50.6mg Injection
The provided text is "undefined," which lacks meaning and cannot be rephrased. A replacement is needed to complete the request.
Uses of Dericip 169.4mg/50.6mg Injection
Managing chronic obstructive pulmonary disease (COPD)
Major Benefits of Dericip 169.4mg/50.6mg Injection:
This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
Common Side effects of Dericip 169.4mg/50.6mg Injection:
- Nausea
- Vomiting
- Headache
- Restlessness
How to use Dericip 169.4mg/50.6mg Injection:
This medication will be administered by your physician or their designated nurse; self-medication is strictly prohibited.
How Dericip 169.4mg/50.6mg Injection works:
Etofylline and theophylline, combined in Dericip 169.4mg/50.6mg Injection, act as bronchodilators. By relaxing airway muscles, they increase airflow, thereby improving breathing.
SAFETY ADVICE
AlcoholUNSAFE
Alcohol consumption alongside Dericip 169.4mg/50.6mg Injection is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The use of Dericip 169.4mg/50.6mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible dangers prior to prescribing. Patient consultation with their doctor is advised.
Breast feedingSAFE IF PRESCRIBED
Lactation is compatible with Dericip 169.4mg/50.6mg Injection. Research in humans indicates negligible transfer of the medication into breast milk, posing minimal risk to the infant. Post-injection, a 2-4 hour delay in breastfeeding may further reduce infant drug exposure.
DrivingCONSULT YOUR DOCTOR
The effect of Dericip 169.4mg/50.6mg Injection on driving ability is unknown. Refrain from driving if experiencing symptoms impairing concentration or reaction time.
KidneyCONSULT YOUR DOCTOR
Data regarding Dericip 169.4mg/50.6mg Injection use in patients with renal impairment is scarce. Physician consultation is advised.
LiverCAUTION
For individuals with hepatic impairment, administration of the Dericip 169.4mg/50.6mg Injection requires careful monitoring. Dosage modification of Dericip 169.4mg/50.6mg Injection might be necessary. Physician consultation is advised.
What if you forget to take Dericip 169.4mg/50.6mg Injection :
Omit a scheduled Dericip 169.4mg/50.6mg Injection? Seek medical advice immediately.
Facts to Know About Dericip 169.4mg/50.6mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Breathing |
3,018 People bought this recently